TipRanks
Pharming Group (NL:PHARM)
:PHARM
Netherlands Market
PHARM
Pharming Group
RESEARCH TOOLSreports
Want to see NL:PHARM full AI Analyst Report?

Pharming Group (PHARM) Stock News & Sentiment

34 Followers
Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38
Premium
Ratings
Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38
9d ago
PHAR
Pharming Group Installs Interim Co-CEOs as Board and CEO Part Ways Over Strategy
Premium
Company Announcements
Pharming Group Installs Interim Co-CEOs as Board and CEO Part Ways Over Strategy
11d ago
Pharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS Patients
Premium
Company Announcements
Pharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS Patients
14d ago
Pharming posts positive Phase II data for leniolisib in rare immune disorders
Premium
Company Announcements
Pharming posts positive Phase II data for leniolisib in rare immune disorders
18d ago
Pharming wins FDA nod to extend Joenja use to younger APDS children
Premium
Company Announcements
Pharming wins FDA nod to extend Joenja use to younger APDS children
28d ago
Pharming Group Steps Up Investor Outreach With September Conference Lineup
Premium
Company Announcements
Pharming Group Steps Up Investor Outreach With September Conference Lineup
1M ago
Pharming launches Joenja in Japan, first market to treat APDS children from age four
Premium
Company Announcements
Pharming launches Joenja in Japan, first market to treat APDS children from age four
2M ago
More NL:PHARM News >

PHARM News on the Web

Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
TipRanks News
Neutral
Pharming launches Joenja in Japan, first market to treat APDS children from age four
TipRanks News
Bullish
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
TipRanks News
Bullish
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
TipRanks News
Bullish
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
TipRanks News
Bullish
Pharming’s Joenja granted marketing authorization by European Commission
TipRanks News
Bullish
Pharming initiated with a Buy at Canaccord on growth potential
TipRanks News
Bullish
Pharming initiated with a Buy at Canaccord
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average2.75 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NL:PHARM’s Media Buzz Sentiment?
Currently, no data Available
What is NL:PHARM’s weekly average amount of articles?
In an average week, 2.75 articles about NL:PHARM are published.
    What is NL:PHARM’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    AMGNAmgen
    MCKMcKesson
    ONCBeOne Medicines
    NVSNovartis
    NTRANatera
    Showing the stocks with the most bullish news sentiment over the past week